Skip to main content

REVIEW article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1394057
This article is part of the Research Topic Transplantation and Cellular Therapy in Lymphomas and Plasma Cell Disorders View all 11 articles

CAR T-Cell for Aggressive Lymphomas Chimeric Antigen Receptor (CAR) T-Cell Therapy for Aggressive B Cell Lymphomas

Provisionally accepted
Bei Hu Bei Hu 1*Victoria Korsos Victoria Korsos 2M. L. Palomba M. L. Palomba 3
  • 1 Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, United States
  • 2 Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • 3 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States

The final, formatted version of the article will be published soon.

    Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA approved CAR T-cell products for aggressive B cell lymphoma, including diffuse large b cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.

    Keywords: Chimeric Antigen Receptor T Cell Therapy (CAR T cell therapy), Diffuse large B cell lymphoma (DLBCL), High grade B cell lymphoma, mantle cell lymphoma (MCL), Relapsed and refractory lymphoma

    Received: 29 Feb 2024; Accepted: 21 May 2024.

    Copyright: © 2024 Hu, Korsos and Palomba. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Bei Hu, Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.